0001178913-21-001087 | 20-F | XBRL Viewer

Severance pay obligations, net

243

122

TOTAL NON-CURRENT LIABILITIES

324

192

TOTAL LIABILITIES

3,597

4,784

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:

Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2020 and December 31, 2019, 140,010,000 shares; issued and outstanding: as of December 31, 2020, and December 31, 2019 21,057,922 and 17,864,684 shares, respectively

^[1]

Accumulated other comprehensive income

Other reserves

8,924

11,398

Additional paid in capital

70,595

63,392

Accumulated deficit

(72,895)

(62,912)

TOTAL SHAREHOLDERS' EQUITY

6,665

11,919

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$ 10,262

$ 16,703

[1]	Represents an amount less than one thousand US dollars.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - ₪ / shares	Dec. 31, 2020	Dec. 31, 2019	Mar. 17, 2013
Statement of financial position [abstract]
Ordinary Shares, par value	₪ 0.0000769	₪ 0.0000769	₪ 0.0000769
Ordinary Shares, Authorized	140,010,000	140,010,000
Ordinary Shares, Issued	21,057,922	17,864,684
Ordinary Shares, Outstanding	21,057,922	17,864,684

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Profit or loss [abstract]
REVENUE	$ 365	$ 236	$ 500
COST OF REVENUE	209	210
RESEARCH AND DEVELOPMENT EXPENSES, NET	6,398	7,199	8,518
GENERAL AND ADMINISTRATIVE EXPENSES	4,891	4,281	2,843
OPERATING LOSS	11,133	11,454	10,861
FINANCIAL INCOME:
Income from change in fair value of financial liabilities at fair value through profit or loss, net	(1,237)	(743)	(523)
Other financial expenses (income), net	67	84	(34)
FINANCIAL INCOME, net	(1,170)	(659)	(557)
LOSS BEFORE TAXES	9,963	10,795	10,304
TAXES ON INCOME	20
NET COMPREHENSIVE LOSS FOR THE YEAR	$ 9,983	$ 10,795	$ 10,304
LOSS PER ORDINARY SHARE:
Basic	$ 0.54	$ 0.89	$ 1.30
Diluted	$ 0.55	$ 0.89	$ 1.31
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES:
Basic	18,417,093	12,146,729	7,955,447
Diluted	18,563,675	12,146,729	7,983,402

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)
$ in Thousands

Number of ordinary shares [Member]

Accumulated other comprehensive income [Member]

Other reserves [Member]

Additional paid in capital [Member]

Accumulated deficit [Member]

Total

BALANCE at Dec. 31, 2017

^[1]

$ 41

$ 7,361

$ 2,853

$ (41,813)

$ (31,558)

BALANCE, shares at Dec. 31, 2017

4,490,720

CHANGES DURING THE YEAR ENDED DECEMBER 31

Net loss for the year

(10,304)

Issuance of shares and warrants, net

^[1]

427

8,011

8,438

Issuance of shares and warrants, net, shares

1,410,000

Conversion of Preferred shares into Ordinary shares

^[1]

32,621

Conversion of Preferred shares into Ordinary shares, shares

4,905,420

Conversion of convertible loan into Ordinary shares

^[1]

4,138

Conversion of convertible loan into Ordinary shares, shares

622,180

Classification of Warrants to purchase preferred shares and shares into Warrants to purchase ordinary shares

5,548

Reclassification due to share-based compensation expired

(1,195)

1,195

Exercise of options to ordinary shares

^[1]

(304)

304

Exercise of options to ordinary shares, shares

31,460

Vested restricted share units

Share-based compensation

1,233

Reclassification of capital contribution from controlling shareholder

(51)

BALANCE at Dec. 31, 2018

^[1]

13,019

49,173

(52,117)

10,116

BALANCE, shares at Dec. 31, 2018

11,459,780

CHANGES DURING THE YEAR ENDED DECEMBER 31

Net loss for the year

(10,795)

Conversion of Preferred shares into Ordinary shares

Conversion of convertible loan into Ordinary shares

Exercise of options to ordinary shares

^[1]

(586)

724

138

Exercise of options to ordinary shares, shares

662,251

Issuance of shares due to exercise of right to purchase ordinary shares

^[1]

(99)

199

100

Issuance of shares due to exercise of right to purchase ordinary shares, shares

32,500

Issuance of shares and warrant due to a private placement, net of issuance costs

^[1]

205

10,672

10,877

Issuance of shares and warrant due to a private placement, net of issuance costs, shares

5,710,153

Vested restricted share units

Reclassification due to share-based compensation and warrants expired

(2,624)

2,624

Share-based compensation

1,483

BALANCE at Dec. 31, 2019

^[1]

11,398

63,392

(62,912)

$ 11,919

BALANCE, shares at Dec. 31, 2019

17,864,684

CHANGES DURING THE YEAR ENDED DECEMBER 31

Net loss for the year

(9,983)

$ (9,983)

Conversion of Preferred shares into Ordinary shares

Conversion of convertible loan into Ordinary shares

Exercise of options to ordinary shares

^[1]

(35)

103

Exercise of options to ordinary shares, shares

31,954

Issuance of shares and warrant due to a private placement, net of issuance costs

^[1]

573

Issuance of shares and warrant due to a private placement, net of issuance costs, shares

337,553

Issuance of shares due to the ATM program, net of issuance costs

^[1]

3,187

Issuance of shares due to the ATM program, net of issuance costs, shares

2,802,731

Expiration of options and warrants

(3,300)

3,300

Vested restricted share units

^[1]

(40)

Vested restricted share units, shares

21,000

Share-based compensation

901

BALANCE at Dec. 31, 2020

^[1]

$ 41

$ 8,924

$ 70,595

$ (72,895)

$ 6,665

BALANCE, shares at Dec. 31, 2020

21,057,922

[1]	Represents an amount of less than one thousand.

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS USED IN OPERATING ACTIVITIES:
Net loss for the year	$ (9,983)	$ (10,795)	$ (10,304)
Adjustments required to reflect net cash used in operating activities (see appendix A)	(440)	1,876	508
Net cash used in operating activities	(10,423)	(8,919)	(9,796)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
Restricted deposits	(33)	(14)
Short-term bank deposits		4,000	(4,000)
Purchase of property and equipment	(53)	(40)	(68)
Net cash provided by (used in) investing activities	(86)	3,946	(4,068)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
Principle element of lease payments	(136)	(114)
Issuance of ordinary shares and warrants, net of issuance costs	798	12,528	9,624
Issuance of shares due to the ATM program, net of issuance costs	3,187
Proceeds from exercise of warrants		100
Proceeds from exercise of options	68	138
Net cash provided by financing activities	3,917	12,652	9,624
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(6,592)	7,679	(4,240)
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	15,185	7,506	11,746
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	8,593	15,185	7,506
Adjustments required to reflect net cash used in operating activities:
Depreciation	225	238	54
Change in fair value of financial liabilities at fair value through profit or loss	(1,237)	(743)	(523)
Issuance costs		164	270
Financial expenses, net	55	10	21
Net changes in severance pay obligation	11	5	(5)
Share-based compensation	901	1,483	1,233
Total adjustments	(45)	1,157	1,050
Changes in working capital:
Decrease (increase) in accounts receivable	23	447	(725)
Decrease (increase) in other current assets	(55)	61	451
Increase (decrease) in accounts payable:
Trade	(170)	(139)	(123)
Other	(40)	280	(334)
Increase (decrease) in contract liabilities	(109)	42	225
Changes in working capital	(351)	691	(506)
Cash used for operating activities:
Interest received		83
Interest paid	(44)	(55)	(36)
Cash used for operating activities	(440)	1,876	508
Supplementary information on investing and financing activities not involving cash flows:
Conversion of preferred shares into ordinary shares			32,621
Conversion of convertible loan into ordinary shares			4,138
Right of use assets obtained in exchange for new operating lease liabilities	258	224
Vested restricted shares units

GENERAL INFORMATION

12 Months Ended

Dec. 31, 2020

Disclosure of general information [abstract]

GENERAL INFORMATION

NOTE 1 - GENERAL INFORMATION:

General:

Entera Bio Ltd. (collectively with its subsidiary, the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. On January 8, 2018 the Company incorporated Entera Bio Inc., a fully owned subsidiary incorporated in Delaware USA. The Company is a leader in the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism, are based on its proprietary technology platform and are both in Phase 2 clinical development. The Company also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has completed one such collaboration with Amgen Inc.

The Company's securities have been listed for trading on the Nasdaq Capital Market since the Company’s initial public offering in July 2018, where a total of 1,400,000 new ordinary shares were issued in consideration of net proceeds of $9.6 million, after deducting offering expenses (see note 10b).

On December 10, 2018, the Company entered into a research collaboration and license agreement (the “Amgen Agreement”) with Amgen Inc. (“Amgen”) in inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement, the Company and Amgen use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has options to select up to two additional programs to include in the collaboration. Amgen is responsible for the clinical development, regulatory approval, manufacturing and worldwide commercialization of the programs.

The Company granted Amgen an exclusive, worldwide, sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed through the performance of the collaboration is to be determined by U.S. patent law. See additional information in note 12.

Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $72.9 million through December 31, 2020 and negative cash flows from operating activities. The Company's management is of the opinion that its available funds as of December 31, 2020 will allow the Company to operate under its current plans into the second quarter of 2022. These factors raise substantial doubt as to the Company's ability to continue as a going concern.

Management is in the process of evaluating various financing alternatives in the public or private equity markets, government grants or through license of the company's technology to additional external parties through partnerships or research collaborations as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no certainty about the Company's ability to obtain such funding.

The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. If the Company does not raise the requisite funds, it will need to curtail or cease operations. These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

COVID-19 pandemic

In December 2019, a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. Starting in March 2020, this virus began to spread globally, including to the United States and Israel and continues to spread globally. The spread of COVID-19 from China to other countries has resulted in the Director General of the World Health Organization declaring the outbreak of COVID-19 as a pandemic. The COVID-19 outbreak continues to rapidly evolve.

In March 2020, the Government of Israel, where the Company operates its research and development activities and clinical trials, imposed a mandatory quarantine of all foreign visitors and, in addition, announced that non-Israeli residents or citizens traveling from certain countries may be denied entry into Israel. Israel has further issued regulations imposing partial home confinement and other movement restrictions, reducing staffing of non-essential businesses, restricting public transportation and other public activities. The Company continues to monitor its operations and government regulations, guidelines and recommendations and may temporarily close its office space to protect its employees. In addition, hospitals may reduce staffing and have begun to reduce or postpone certain treatments in response to the spread of an infectious disease, including its clinical trials. Disruptions to the supply chain may prevent the Company from receiving necessary materials from manufacturers for the Company's research and may also delay third-party laboratories with which the Company works from performing research tasks.

Israeli authorities have begun repurposing certain medical institutions to function as centers for COVID-19 treatment, including two centers where the Company conduct trials. These disruptions may prevent or delay the completion of research and development activities and the clinical trials on the expected timelines. In addition, interruption or delays in the operations of the FDA and foreign regulatory authorities may impact review and approval timelines.

The extent to which the coronavirus impacts the Company's business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and geographic reach of the coronavirus and the effectiveness of actions to contain the coronavirus or treat its impact, among others.

Approval of financial statements

These financial statements were approved by the Company's Board of Directors on March 17, 2021.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2020

Disclosure of summary of significant accounting policies [abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of preparation of the financial statements:

The consolidated statements of financial position of the Company as of December 31, 2020 and 2019, and the related consolidated statements of comprehensive loss, changes in shareholders' equity (capital deficiency) and consolidated statement of cash flows for each of the three years ended December 31, 2020 have been prepared in accordance with International Financial Reporting Standards, ("IFRS"), as issued by the International Accounting Standards Board ("IASB").

The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated.

The financial statements have been prepared under the historical cost except for financial liabilities at fair value through profit or loss.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 3. Actual results could differ from those estimates and assumptions.

Functional and presentation currency:

Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The U.S. dollar is the currency of the primary economic environment in which the operations of the Company is conducted. The consolidated financial statements are presented in U.S. dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the statements of comprehensive loss within financial income or expenses.

Translation differences on non-monetary financial assets and liabilities at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss within financial income or expenses.

Basis of consolidation

The consolidated financial statements include the accounts of the Company and its subsidiary, Entera Bio Inc. Intercompany transactions and balances have been eliminated upon consolidation.

Cash and cash equivalents

Cash and cash equivalents include cash on hand and short-term bank deposits (with original maturities of three months or less) that are not restricted as to withdrawal or use and are therefore considered to be cash equivalents.

Short-term bank deposits

Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. The fair value of short-term bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates.

Restricted deposits

Restricted deposits relate to accounts where withdrawals are restricted under contractual agreements.

Property and equipment

Property and equipment are stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Repairs and maintenance are charged to the statement of comprehensive loss during the period in which they are incurred.

The assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives, as follows:

	Years
Compute equipment		3-5
Office furniture		5
Lab equipment		7-10
Leasehold improvements*		3-5

*Leasehold improvements are depreciated over the lease period or the expected useful life of the improvements, whichever is shorter.

Intangible assets:

Research and development expenses

Research expenses are charged to profit or loss as incurred. An intangible asset arising from development of the Company's products is recognized if all of the following conditions are met:

•

It is technically feasible to complete the intangible asset so that it will be available for use;

•

Management intends to complete the intangible asset and use it or sell it;

•

There is an ability to use or sell the intangible asset;

•

It can be demonstrated how the intangible asset will generate probable future economic benefits;

•

Adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are available; and costs associated with the intangible asset during development can be measured reliably.

Other development costs that do not meet the above criteria are recognized as expenses as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period.

As of December 31, 2020, the Company has not capitalized development costs.

In process research and development (IPR&D)

IPR&D acquired is presented based on the fair value at the date of the acquisition and tested annually for impairment.

Impairment of non-financial assets

Intangible assets that are not subject to amortization are tested annually for impairment. Assets that are subject to depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to dispose and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).

For the years ended December 31, 2020 and 2019, no impairment has been recognized.

Leases

At inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company reassesses whether a contract is, or contains, a lease only if the terms and conditions of the contract are changed.

Commencing January 1, 2019, leases are recognized as a right-of-use asset and a corresponding liability at the same amount as of the date in which the leased asset is available for use by the Company. Each payment is allocated between the liability and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The right-of-use asset is depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis.

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the future expected lease payments during the lease term.

The lease term includes extension options (or periods after termination options) if the lease is reasonably certain to be extended (or not terminated). The lease payments during the term of the lease are discounted using the interest rate implicit in the lease. If that rate cannot be determined, the lessee’s incremental borrowing rate is used, being the rate that the lessee would have to pay to borrow the funds necessary to obtain an asset of similar value in a similar economic environment with similar terms and conditions.

Payments associated with short-term leases (leases with a lease term of 12 months or less) and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss.

Until 2019, leases were classified as either finance or operating leases. Payments made under operating leases (net of any incentives received from the lessor) were charged to profit or loss on a straight-line basis over the period of the lease.

See also note 9.

Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment.

Financial instruments

Accounts receivables are classified at amortized cost. This category is subject to an impairment test under the expected credit losses model in accordance with IFRS 9.

Warrants

Receipts in respect of warrants are classified as equity to the extent that they confer the right to purchase a fixed number of shares for a fixed exercise price. In the event that the exercise price is not deemed to be fixed, the warrants are classified as a derivative financial liability. This liability is initially recognized at its fair value on the date the contract is entered into and subsequently accounted for at fair value at each reporting date. Gains or losses arising from changes in the fair value of financial liabilities at fair value through profit or loss are presented in the statement of comprehensive loss under "financial income" or "financial expenses". Transaction costs recorded as an expense when they occur.

Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are included in equity as a deduction from the proceeds.

Deferred income tax

Deferred income taxes are recognized using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred income tax assets are recognized only to the extent that it is probable that future taxable income will be available against which the temporary differences can be utilized. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

In the absence of expectation of taxable income in the future, no deferred tax assets are recorded in the financial statements.

Share-based payments

In 2018 and 2013, the Company adopted share-based compensation plans for employees, directors and service providers. As part of the plans, the Company grants employees, directors and service providers, from time to time and at its discretion, options to purchase Company's ordinary shares. The fair value of the employees', directors' and service providers' services received in exchange for the grant of the options is recognized as an expense in the statement of comprehensive loss. The total amount recognized as an expense over the vesting period of the options was determined by reference to the fair value of the options granted at the date of grant. The option's grants for service providers measured at fair value according the services that will be provide.

Service conditions and performance vesting conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognized over the vesting period when the performance condition is probable. The vesting period is the period over which all of the specified vesting conditions are to be satisfied.

At the end of each reporting period, the Company revises its estimates of the number of options that are expected to vest based on the service conditions and performance conditions. The Company recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive loss, with a corresponding adjustment to "other reserves".

When options are exercised, the Company issues new shares, with proceeds less directly attributable transaction costs recognized as share capital (par value) and additional paid in capital.

Revenue recognition:

The Company recognized revenue from the Amgen Agreement which was signed in December 2018 according to IFRS 15, "Revenues from Contracts with Customers”. Prior to the signing of the Amgen Agreement in 2018, the Company did not have revenue transactions.

In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:

Identification of the contract, or contracts, with a customer.

Identification of the performance obligations in the contract.

Determination of the transaction price.

Allocation of the transaction price to the performance obligations in the contract.

Recognition of revenue.

On December 10, 2018, the Company entered into the Amgen Agreement in inflammatory disease and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable initial access payment of $725 thousand from Amgen in January 2019. The Company identified two promises in the agreement: a license to use the Company's proprietary drug delivery platform and pre-clinical research and development services (“pre-clinical R&D services”). The preclinical R&D services include discovery, research and design preclinical activities relating to the programs selected by Amgen.

Each of these promises met the definition of distinct performance obligation. The Company evaluated the standalone selling price of the pre-clinical R&D services at $225 thousand and the right to use the intellectual property at $500 thousand.

The Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately from the pre-clinical R&D services since the Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore, the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to Amgen on December 10, 2018.

Revenues attributed to the preclinical R&Ds services are recognized during the period of the pre-clinical R&D services, over time according to the input model method on a cost-to-cost basis.

Under IFRS 15, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events of development and commercial progress, are a form of variable consideration. When assessing the portion, if any, of such milestone-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome. The Company then evaluates if any of the variable consideration determined in the first step is constrained. Variable consideration is included in the transaction price if, in the Company’s judgment, it is highly probable that a significant future reversal of cumulative revenue under the contract will not occur. Estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of the Company’s anticipated performance and all information (historical, current and forecasted) that is reasonably available. The Company did not recognize any revenues from any potential milestone payments.

An entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

The subsequent sale or usage occurs; and

The performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially satisfied).

As royalties are payable based on future commercial sales, as defined in the agreement, which did not occur as of the date of the financial statements, the Company did not recognize any revenues from royalties. See additional information in note 12.

Government grants

Government grants, which are received from Israel Innovation Authority (the "IIA") by way of participation in research and development that is conducted by the Company, fall within the scope of "forgivable loans", as set forth in IAS 20 "The Accounting Treatment of Government Grants and Disclosure in respect of Government Assistance". Since at the time of the receipt of the grants there is no reasonable assurance that the grants that have been received will be repaid, at the time of their receipt they are offset against the related research and development expenses in the statement of comprehensive loss. To the extent that it is considered "more likely than not" that the grants will be repaid in the future, the Company would record a financial liability. Other government grants which are not subject to royalties are offset against related research and development expenses in the statements of comprehensive loss.

Loss per ordinary share

Basic loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares issued and outstanding during the year. In computing diluted loss per share, the basic loss per share is adjusted to take into account the potential dilution that could occur upon the conversion of any dilutive financial instruments by subtracting from net loss the fair value changes of such financial instruments, and by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all such dilutive potential shares. As of December 31, 2020, and 2019, the Company’s dilutive potential shares consisted of options and warrants. Prior to the Company’s IPO, the dilutive potential shares consisted of shares issuable upon conversion of convertible loan and preferred shares, warrants and options. Potential shares are only dilutive if their conversion would increase the loss per share. If the loss per share would decrease, the shares are anti-dilutive and are excluded from the diluted loss per share calculation.

Recently Issued Accounting Pronouncements

In September 2019, the IASB has issued amendments to IFRS 9 Financial Instruments, IAS 39 Financial Instruments: Recognition and Measurement and IFRS 7 Financial Instruments: Disclosures that provide certain reliefs in connection with interest rate benchmark reform. The reliefs relate to hedge accounting and have the effect that InterBank Offered Rate (IBOR) reform should not generally cause hedge accounting to terminate. However, any hedge ineffectiveness should continue to be recorded in the income statement. Given the pervasive nature of hedges involving IBOR-based contracts, the reliefs will affect companies in all industries.

These amendments should be applied for annual periods beginning on or after January 1, 2020. Since the Company does not have financial instruments designated under hedge accounting, the amendments will not have an impact on its consolidated financial statements.

CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	12 Months Ended
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	Dec. 31, 2020
Disclosure of critical accounting estimates and judgements [abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	NOTE 3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below: Fair value of financial liabilities at fair value through profit or loss To determine the fair value of Company’s financial instruments classified as financial liabilities, the Company uses its judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period or measurement date as well as using management judgment. In addition, these liabilities are based on estimates that are subject to change based on the facts and circumstances at the times the estimates are made. See note 4. Revenue recognition With respect to the Amgen Agreement the Company used its judgement to identify the Company's promises in the agreement and whether the promises are distinct performance obligation. In addition, the Company used its judgement to determine the allocation of the transaction price between its identified distinct performance obligations. The Company also used its significant judgment in order to determine the R&D services period. See note 12.

FINANCIAL INSTRUMENTS

12 Months Ended

Dec. 31, 2020

Disclosure of detailed information about financial instruments [abstract]

FINANCIAL INSTRUMENTS

NOTE 4 - FINANCIAL INSTRUMENTS:

Financial risk management:

Financial risk factors

The Company’s activities expose it to a variety of financial risks. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance.

Risk management is performed by the Chief Financial Officer of the Company, who identifies and evaluates financial risks in close cooperation with the Company's Chief Executive Officer.

The Company does not use financial instruments for hedging activity.

Credit risk

Credit and interest risk arise from cash and cash equivalents and deposits with banks. The Company estimates that since the liquid instruments are mainly invested for the short-term and with a highly-rated institution, the credit and interest risk associated with these balances is immaterial.

Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash.

The Company is in a research stage and has not yet generated significant revenues from its activity. It is therefore exposed to liquidity risk, taking into consideration the forecasts of cash flows required to finance its operations and other activities.

Market risk-Foreign exchange risk

The Company might be exposed to foreign exchange risk as a result of making payments to employees or service providers and investment of some liquidity in currencies other than the Company's functional currency. The Company manages the foreign exchange risk by aligning the currencies for holding liquidity with the currencies of expected expenses, based on the expected cash flows of the Company.

Capital risk management

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. It should be noted that the Company is in the research and development stage and has not yet generated significant revenues.

Fair value of financial instruments

The different levels of valuation of financial instruments are defined as follows:

Level 1 Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).

Level 3 Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value of financial instruments traded in active markets is based on quoted market prices at the dates of the statements of financial position.

A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis. These instruments are included in level 1.

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

As of December 31, 2020, and 2019, the fair value of cash and cash equivalents, accounts receivable, other receivables and accounts payable approximates their carrying value.

Classification of financial instruments by groups:


	Financial liabilities at fair value through profit or loss		Financial liabilities at amortized cost		Total
	U.S. dollars in thousands

As of December 31, 2020:
Trade and other payable		-		1,494		1,494
Warrants to purchase ordinary shares (Level 1) (1)		239		-		239
Warrants to purchase ordinary shares (Level 3) (2)		1,193		-		1,193
Lease liabilities				432		432
		1,432		1,926		3,358

As of December 31, 2019:
Trade and other payable		-		1,704		1,704
Warrants to purchase ordinary shares (Level 1) (1)		266		-		266
Warrants to purchase ordinary shares (Level 3) (2)		2,178		-		2,178
Lease liabilities		-		299		299
		2,444		2,003		4,447

(1) Tradable warrants presented above are valuated based on the market price (a Level 1 valuation).

(2) Warrants to purchase ordinary shares issued in December 2019 and February 2020 are valuated based on the Monte-Carlo pricing model (a Level 3 valuation).

The main assumptions used are as follows:

	December 31			December 31
	2020			2019
Price per share	$	1.08		$	1.84-$2.07
Volatility		66	%		62%-63	%
Expected term		2			3
Risk free interest rate		0.1%-0.13	%		1.63%-1.71	%
Expected dividend		0	%		0	%

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2020

Disclosure of detailed information about intangible assets [abstract]

INTANGIBLE ASSETS

NOTE 5 - INTANGIBLE ASSETS:

On June 1, 2010 D.N.A. Biomedical Solutions Ltd. ("D.N.A.") and Oramed Ltd., ("Oramed") entered into a joint venture agreement, (the "Joint Venture Agreement") for the establishment of Entera Bio Ltd. According to the Joint Venture Agreement each of D.N.A. and Oramed acquired 50% of the Company's ordinary shares. D.N.A invested $600,000 in the Company, and Oramed and the Company entered into a Patent License Agreement pursuant to which Oramed licensed to the Company certain of Oramed's patent (the “IPR&D”). The IPR&D was recorded as an intangible asset based on its fair value.

On February 22, 2011, Oramed and the Company entered into a patent transfer agreement, (the "Patent Transfer Agreement"), that superseded the Patent License Agreement, whereby Oramed assigned to the Company all of its rights, title and interest to its patent that Oramed licensed to the Company in 2010, under certain conditions. Under this agreement, the Company is obligated to pay Oramed royalties equal to 3% of its net revenues (as defined in the Patent Transfer Agreement).

The Company tests intangible assets for impairment at least once a year at December 31 by calculating the recoverable amount of the cash generating unit to which the intangible asset belongs, which is the Company as a whole. The recoverable amount is calculated based on a fair value less cost to sell. For the purpose of calculating fair value of the Company's equity as of December 31, 2020 and December 31, 2019, the Company applied the market approach and calculated its enterprise value based on the quoted price per share.

CONVERTIBLE LOANS

12 Months Ended

Dec. 31, 2020

Disclosure of detailed information about borrowings [abstract]

CONVERTIBLE LOANS

NOTE 6 - CONVERTIBLE LOANS:

As of December 31, 2020, and 2019, there were no convertible loans outstanding. The convertible loans as described below were eventually converted into ordinary shares of the Company upon the closing of the Company’s initial public offering in July 2018.

During 2012 through 2016, the Company entered into several convertible loan agreements with certain lenders for the aggregate amount of $12.4 million. Each of the loans bears interest at a rate between 0.6% to 5% per year, which is to be repaid as described in each agreement. The lenders had the right to convert the loan into the Company's ordinary shares upon a specific transaction (Such as, an IPO) as detailed in each loan agreement, as follows:

2012 Convertible Loan in an aggregate amount of $4.1 million. Following the Closing of the IPO (see note 10b below), the Company’s outstanding 2012 Convertible loans in the amount of $4.1 million were automatically converted into 622,180 Ordinary Shares of the Company.

2015 Convertible Loan in an aggregate amount of $2.0 million, of which $1.1 million repaid in 2017 (as exchange to 2016 convertible loan) and the remaining $0.9 million have been repaid in 2017 as well. In connection with the 2015 Convertible Loan, the Company issued to the lenders warrants to purchase additional shares equal to 40% of the shares issued upon conversion of the loan.

2016 Convertible Loan in an aggregate amount of approximately $7.4 million. In connection with the 2016 Convertible Loan, the Company issued to the lenders warrants to purchase additional shares equal to 40% of the shares issued upon conversion of the loan. The warrant will be exercisable for 4 years from the grant date. See also note 10b.

As described in note 10b, as part of the Series B preferred share purchase agreement, the 2016 convertible loan together with the accrued interest was converted into 1,719,770 series B-1 preferred shares at a price per share of $5.24. At that time, the 2016 Warrants became warrant to purchase Series B preferred shares at an exercise price of $6.99.

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES

12 Months Ended

Dec. 31, 2020

Disclosure of preferred shares and warrants to prefered shares [abstract]

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES

NOTE 7 - PREFERRED SHARES AND WARRANTS TO PREFERED SHARES:

As of December 31, 2020, and 2019, there were no preferred shares outstanding. The preferred shares converted into ordinary shares of the Company upon the closing of the Company’s initial public offering in July 2018. See also note 10b.

During 2014 through 2018, the Company entered into a Preferred Share Purchase Agreements (the Series A agreements) and its amendments with Centillion and certain shareholders (the “Investors”), the Company issued 10,222 preferred A shares and 2,554 warrants to purchase preferred A shares for an aggregate purchase price of approximately $5 million.

For accounting of purposes, the preferred shares and warrants to preferred shares were classified as a financial liability and measured at fair value through profit or loss at each balance sheet date up to July 2, 2018.

On July 2, 2018, following the Closing of the IPO, the Company’s 10,222 preferred A shares were automatically converted into 1,328,860 ordinary shares of the Company (after the share split). In addition, the 2,554 (before stock split) warrants to purchase preferred A shares were converted into 332,020 warrants to purchase ordinary shares of the Company. In addition, existing options to purchase Series A preferred shares and warrants to purchase Series A preferred shares, granted to certain holders of our Series A preferred shares that were exercisable upon the closing of the IPO, were automatically converted into options to purchase 387,530 ordinary shares of the Company and into warrants to purchase 85,931 ordinary shares of the Company.

In 2017, the Company entered into a Series B preferred share purchase agreement (the “Preferred B Financing”), with certain investors, including D.N.A and Centillion (together, the “Investors”). Pursuant to the terms of the agreement, the Company issued 14,283 Series B preferred shares for an aggregate purchase price of $12.1 million, net of issuance costs. The Company also issued to a broker dealer, a warrant to purchase 526 Series B preferred shares, at a price of $908.78 per share and recorded additional issuance costs of $198 thousand.

The Preferred B Financing constitutes a Triggering Event as defined in the 2016 Convertible Loan and as a result, the entire loan amount under the 2016 Convertible Loan, together with accrued interest in the amount of $9.0 million, was automatically converted into 13,229 Series B-1 preferred shares at a price per share of $681.585 and the warrants issued became warrants to purchase Series B preferred shares at an exercise price of $908.78. The rights of the Series B-1 preferred shares are identical in all respects (other than the price per share) to the Series B preferred shares.

On July 2, 2018, following the Closing of the IPO as described in note 10b, the Company series B preferred shares and series B-1 preferred shares were automatically converted into 1,856,790 and 1,719,770, Ordinary Shares of the Company, respectively (after the share split).In addition, warrants to purchase Series B preferred shares and warrants to purchase Series B-1 preferred shares were automatically converted into 756,340 and 467,220 warrants, respectively, to purchase Ordinary Shares of the Company. See also note 10b.

COMMITMENTS

12 Months Ended

Dec. 31, 2020

Disclosure of contingent liabilities [abstract]

COMMITMENTS

NOTE 8 - COMMITMENTS:

Pursuant to the Patent Transfer Agreement with Oramed, the Company is committed to pay royalties to Oramed - see also note 5.

The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the Government participates by way of grants. At the time the grants were received, successful development of the related project was not assumed. In the case of failure of the project that was partly financed by the Government of Israel, the Company is not obligated to pay any such royalties. Under the terms of the Company’s funding from the Israeli Government, royalties are payable on sales of products developed from projects so funded of 3% during the first three years, from commencement of revenues, 4% during the subsequent three years and 5% commencing the seventh year up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of annual interest based on Libor. The amount that must be repaid may be increased to three times the amount of the grant received, and the rate of royalties may be accelerated, if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. As of December 31, 2020, the total royalty amount that would be payable by the Company, before the additional Libor interest and payments as described below, is approximately $460,000.

Following the signing of the Amgen Agreement (see note 1a(4)), the Israeli Innovation Authority (the "IIA") determined that the Company should pay 5.38% of each payment that will be received by the Company from Amgen on the license of IP up to 6 times the grant received. As of December 31, 2020, the Company paid $54,000 to the IIA. In January 2021, the Company paid an additional $13,000 to the IIA.

Emisphere Technologies, Inc., or Emisphere, has notified the Company that it believes that it is the exclusive owner of certain U.S. and related foreign patents and patent applications the Company acquired from Oramed Ltd. Emisphere has not initiated a legal proceeding as of the date of the approval of this financial statement. If Emisphere were to initiate a legal proceeding, the Company would vigorously defend against such claim and believe that Emisphere’s notification is without merit.

LEASES

12 Months Ended

Dec. 31, 2020

Presentation of leases for lessee [abstract]

LEASES

NOTE 9 - LEASES:

Effective January 1, 2019, the Company adopted IFRS 16. The Company has not restated prior reporting period, as permitted under the specific transitional provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules are therefore recognized in the opening balance sheet on January 1, 2019.

On initial application, the company recognized lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under the principles of IAS 17 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee’s incremental borrowing rate as of January 1, 2019. The weighted average incremental borrowing rate of the lessee applied to the lease liabilities on January 1, 2019 was 16%. The Company has elected to record right-of-use assets based on the corresponding lease liability.

In applying IFRS 16 for the first time, the Company had used the following practical expedients permitted by the standard:

•

Use of a single discount rate to a portfolio of leases with reasonably similar characteristics;

•

Reliance on previous assessments on whether leases are onerous;

•

Exclusion of initial direct costs for the measurement of the right-of-use asset at the date of initial application;

•

Use of hindsight in determining the lease term where the contract contains options to extend or terminate the lease.

The Company has also elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4, “Determining whether an Arrangement contains a Lease.

Office lease agreement

The Company leases office and research and development space under several agreements. The annual lease consideration is a total of $164 thousand. The lease agreement will expire on June 30, 2023, with a one-time option for early termination by the Company on December 31, 2021, subject to a notice period of six months. These agreements are considered as operating leases and presented under operating lease right-of-use assets.

Starting December 31, 2020, the lease asset and liability excludes the option to terminate the lease period on December 31, 2021.

As of December 31, 2020, the Company provided bank guarantees of approximately $25,000, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.

The Following table is the composition of right-of-use assets by type:

	As of December 31, 2020		As of December 31, 2019		As of January 1, 2019
Facility		306		253		151
Vehicles		50		7		15
Total right-of-use asset		356		260		166

The following table summarize the contractual obligations:

	Payments due by period
	Total		Less than 1 year		1 - 3 years
	(In thousands)
Operating leases for facility and vehicles as of December 31, 2019	$	346	$	177	$	169
Operating leases for facility and vehicles as of December 31, 2020	$	510	$	205	$	305

	Year ended December 31,
	2020		2019

Depreciation expense:
Facility		137		121
Vehicles		7		9
Financial expense		33		55
Cash paid for amounts included in the measurement of lease liabilities		179		169
Right of use assets obtained in exchange for expanded period of operating lease liabilities		258		224

SHARE CAPITAL

12 Months Ended

Dec. 31, 2020

Disclosure of classes of share capital [abstract]

SHARE CAPITAL

NOTE 10 - SHARE CAPITAL:

The share capital composed of ordinary shares of NIS 0.0000769 par value, as follows:

	Number of ordinary shares
	December 31
	2020		2019
Authorized		140,010,000		140,010,000
Issued		21,057,922		17,864,684

The ordinary shares confer upon their holders the following rights: (i) the right to vote in any general meeting of the Company, (ii) the right to receive dividends, if and when declared by the Board of Directors and (iii) the right to receive upon liquidation of the Company a sum equal to the nominal value of the share, and if a surplus remains, to receive such surplus, subject to the rights conferred on any class of shares which may be issued in the future.

Initial Public Offering (“IPO”)

On July 02, 2018 the Company completed the IPO and offered 1,400,000 ordinary shares and 1,400,000 warrants (the “IPO warrants”) to purchase up to 700,000 ordinary shares for a gross consideration of $11.2 million before issuance costs ($9.6 million net of issuance costs in cash which included $0.9 million underwriters’ fees and an additional approximately $0.7 million of other issuance costs). The ordinary shares and the IPO warrants sold in units (each a “unit”), with each unit consisting of one ordinary share and one tradable warrant to purchase 0.5 of an ordinary shares. The public offering price was $8.0 per unit.

The ordinary shares and warrants were immediately separable and started to trade separately upon completion of the Company’s IPO in July 2018.

In Connection with the IPO certain actions were completed, including:

A 1-for- 130 split of the Company's ordinary shares. Following the split, the Company retrospectively reflected the change in the share capital of the Company for all periods presented. Unless otherwise indicated, all of the ordinary share numbers, losses per ordinary share, share prices, options and warrants in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for- 130 split.

The Company’s outstanding 2012 Convertible loans were automatically converted into 622,180 Ordinary Shares of the Company.

The Company's series A preferred shares, series B preferred shares and series B-1 preferred shares were automatically converted into 1,328,860, 1,856,790 and 1,719,770, Ordinary Shares of the Company, respectively.

The Company's warrants to purchase series A preferred shares, warrants to purchase Series B preferred shares and warrants to purchase Series B-1 preferred shares were automatically converted into 332,020, 756,340 and 467,220 warrants, respectively, to purchase ordinary shares of the Company.

Existing options to purchase Series A preferred shares and warrants to purchase Series A preferred shares, granted to certain holders of our Series A preferred shares that were exercisable upon the closing of the IPO, were automatically converted into options to purchase 387,530 Ordinary Shares of the Company and into warrants to purchase 96,980 Ordinary Shares of the Company.

On July 26, 2018, the Company's underwriters exercised their overallotment option to purchase 210,000 warrants to purchase 105,000 Ordinary Shares of the Company for a total consideration of $2,100. The fair value of the warrants on the issuance date was $172,000. The Company recorded the fair value as issuance costs.

The Company also issued to the underwriters 10,000 ordinary shares following the closing of the IPO, as well as 70,000 underwriter warrants at an exercise price of $8.80 to purchase 70,000 ordinary shares. The underwriter warrants may be exercised on a cashless basis under certain circumstances as described in the warrant agreement. The underwriter warrants will be exercisable 180 days following June 29, 2018 until the fifth anniversary of such effective date. The underwriter warrants are not redeemable by the company and have some registration rights as described in the warrant. The underwriter warrants will provide for adjustment of the exercise price of such warrants (and the ordinary shares underlying such warrants) for dilutive events such as a stock dividend or stock split and for recapitalizations, mergers and other fundamental transactions.

The shares and warrants issued to the underwriters were recorded as an issuance cost based on fair value of $66,500 and $255,000 respectively.

The Company allocated the total consideration from the issuance of the units between the ordinary shares and the tradable warrants as follows: the IPO warrants were recorded at fair value based on the quoted price on Nasdaq as of July 2,2018 and the residual amount was allocated to the ordinary shares.

Issuance costs were allocated to the ordinary shares and the IPO warrants according to their fair values. Issuance costs which were allocated to the ordinary shares were deducted from shareholders' equity, and issuance costs that were allocated to the IPO warrants were expensed immediately.

IPO warrants

As described above, the Company issued 1,400,000 IPO warrants to purchase 700,000 ordinary shares of the Company. The IPO warrants are exercisable immediately at an initial exercise price of $8.4 per ordinary share for a period of five years, unless earlier repurchased by the Company under "Fundamental Transactions” as described in the warrant agreement or early expired as described below and in the warrant agreement.

The exercise of the warrants is in cash, unless the warrant holder is utilizing the “cashless” exercise provision of the warrants, prior to the termination date under certain circumstances as described in the warrant agreement. On the termination date, any warrants not previously exercised, repurchased by the Company or subject to early expiration will terminate and expire worthless.

The exercise price and number of shares issuable upon exercise of each warrant are subject to standard adjustments. The exercise price is subject to reduction if, within two years of the date of original issuance of the warrants, the Company sells or grants any warrant or option (except in certain circumstances as described in the warrant) at an effective price per share less than $8.0 per share (as adjusted in proportion with any adjustments made from time to time), which reduction will be based on a weighted average, as described in the warrant.

The Company may accelerate the expiration date of the warrants upon written notice to the holders at any time if the last reported sale price (as defined in the warrants) exceeds $24.00 per share, which is 300% of the IPO price per unit (subject to adjustments) for a 10 consecutive trading day period. As described in note c, the Company completed financing round in a price per share lower than the $8.0, therefore, the adjusted exercise price is $5.85.

For accounting purposes, the IPO warrants issued to the public were classified as a financial liability since their exercise price and number of shares issuable upon exercise of each warrant are subject to certain adjustments as described in the warrant agreement and also due to the cashless exercise option. The fair value of the IPO warrants as of the IPO closing date and as of December 31, 2020 was based on quoted price on Nasdaq (Level 1 valuation) as of the respective date.

In July 2019, one of the Company’ shareholders' exercised his option to acquire 32,500 ordinary shares and additional 8,190 warrants for a total consideration of $100,000 (upon achievement of the second milestone) in accordance with the preferred share A purchase agreement signed in 2014 and its amendments.

On July 20, 2019, the 443,950 warrants and certain additional options to purchase 443,950 ordinary shares for a purchase price of $3.69 per share (upon achievement of the second milestone) in accordance with the abovementioned preferred share A purchase agreement and its amendments expired. Following the expiration, the Company classified $1.4 million from Other Reserves to Additional paid in Capital.

On October 4, 2019 the 467,220 warrants to purchase ordinary shares at a purchase price of $5.24, in accordance with the “2016 Convertible Loan” (Series B-1 preferred shares) expired. Following the expiration, the Company classified $1.2 million from Other Reserves to Additional paid in Capital.

On December 11, 2019 and December 18, 2019 (“the first and second closing”), the Company entered into subscription agreements with a selected group of accredited investors, including certain board members and their affiliates for the private placement of 5,710,153 ordinary shares for aggregate subscription proceeds to the Company of $13.5 million at $2.37 price per share. In addition, the Company granted 2,855,095 warrants, exercisable over a three-years period from the date of issuance, to purchase 2,855,095 ordinary shares at a per share exercise price of $2.96.

In addition, on December 13, 2019, D.N.A Biomedical Solutions Ltd. (“DNA”), an existing shareholder of the Company, subscribed to the Private Placement (the “DNA Private Placement”) to purchase 337,553 ordinary shares for aggregate consideration of $800,000. In connection with the transaction, the Company granted DNA warrants, exercisable over a three-year period from the date of issuance, to purchase 168,776 ordinary shares at a per share exercise price of $2.96. This investment was approved by the shareholders of the Company on February 18, 2020.

The 168,776 warrants issued in connection with the DNA Private Placement together with the 2,855,095 warrants issued in connection with the Private Placement are the “Investors Warrants”

In connection therewith, the Company entered into Placement Agency agreement with GP Numenkari Inc., a broker-dealer (“the Broker”). Based on the agreement, the Broker was entitled to the following consideration:

A cash fees equal to 10% of the total proceeds paid by subscribers invested through the Broker.

Three-years warrants to purchase ordinary shares in the amount equal to 10% of the number of shares issued to subscribers invested through the Broker at a per share exercise price of $2.37 (“Broker Warrants Type 1”).

Three-years warrants to purchase ordinary share in the amount equal to 5% of number of shares issued to subscribers invested through the Broker at a per share exercise price of $2.96 (“Broker Warrants Type 2”), together with the Broker Warrants Type 1 (the “Broker Warrants”).

Following the first and second closing of the offering, the Company issued 184,515 Broker Warrants type 1 and 92,257 Broker Warrants type 2.

Prior to the exercise of the Investor Warrants and the Broker Warrants and for one year from the date of the first closing, the number of ordinary shares issuable upon their exercise and the exercise price are subject to customary adjustments, including in the events of reorganizations or reclassifications of the Company’s capital stock, upon payment of dividends or distributions to the Company’s shareholders, and upon subsequent issuance of the Company’s share capital at or below a price of $2.37. In addition, these warrants agreements have cashless exercise option. Therefore, for accounting purposes, the Investors Warrants issued were classified as a financial liability. As described in note 10i, the Company issued Ordinary Shares through the Company’s ATM Program at an average price per share lower than $2.37, and the adjusted exercise price was reset to $1.05.

The Company had transaction costs of approximately $1.2 million, out of which $205 thousand are stock-based compensation expenses due to issuance of Broker Warrants type 1 and Broker Warrants type 2.

The Company allocated the total consideration from the issuance of the units between the ordinary shares and the warrants as following: the Investors Warrants were recorded at fair value based on its fair value as of the issuance date and the residual amount was allocated to the ordinary shares.

Issuance costs were allocated to the ordinary shares and the tradable warrants according to their fair values. Issuance costs which were allocated to the ordinary shares were deducted from shareholders' equity, and issuance costs that were allocated to the Investors warrants were expensed immediately.

As part of the subscription agreements, the Company also entered into a Registration Rights Agreement (together with the Warrants and the Subscription Agreement), pursuant to which within seven months of the final closing, the Company shall file a registration statement on Form F-3 with the SEC for the resale of the Shares issued in the first and second closing (including those issued upon exercise of the Warrants). Under the agreement, the Company is required to pay the purchasers liquidated damages in the event that the Company does not meet the foregoing requirement in an amount equal to 1% per month of the aggregate purchase price paid in cash by such purchasers for their investment in the Company. In June 2020, the Company filed the selling registration statement on Form F-3 with the SEC.

On June 13, 2020, 687,960 warrants to purchase 687,960 ordinary shares for a purchase price of $6.99 per share in accordance with the Series B preferred share purchase agreement signed in 2016 and its following amendments expired. Following the expiration, the Company classified $1.5 million from Other Reserves to Additional paid in Capital.

In July 2020, 340,210 warrants to purchase 340,210 ordinary shares for a purchase price of $3.69 per share in accordance with the Series A preferred share purchase agreement expired. Following the expiration, the Company classified $1.2 million from Other Reserves to Additional paid in Capital.

On July 4, 2020, the Company established a primary registration statement under form F-3 and at-the-market equity program (the "ATM Program") that allows the Company to issue up to $13.9 million of ordinary shares, at the Company's discretion. Distributions of the ordinary shares through the ATM Program were made pursuant to the terms of an equity distribution agreement dated July 13, 2020 among the Company and Canaccord Genuity LLC (the "Agent").

As of December 31, 2020, the Company issued 2,802,731 ordinary shares for gross proceeds of $3.5 million at a weighted average price of $1.27 per ordinary share through the Company’s ATM Program. The net consideration from ATM Program was $3.2 million. These transactions triggered adjustment to the exercise price of the warrant issued as part of the Private Placement held in December 2019 and February 2020. See note 10f.

Share based compensation:

Share based compensation plan

On March 17, 2013, the Company's Board of Directors approved a Share Incentive Plan (the “2013 Plan”). Under the 2013 Plan, the Company shall reserve sufficient number of ordinary shares, NIS 0.000769 par value, of the Company for allocation of stock options, restricted share units, restricted share awards and performance-based awards (the "Option"), to employees and non-employees. Each Option is exercisable for one ordinary share.

Any option granted under the 2013 Plan that is not exercised within six years from the date upon which it becomes exercisable will expire.

On July 2, 2018, the Company's board of directors and shareholders of the Company approved a new Share Incentive Plan (the “2018 Plan”) and reserved 1,371,398 ordinary shares of the Company for allocation of stock options, restricted share units, restricted share awards and performance-based awards (the "Option"), to employees and non-employees for issuance under the 2018 Plan. Each Option is exercisable for one ordinary share NIS 0.0000769 par value.

Any option granted under 2018 Plan that is not exercised within 10 years from the date upon which it becomes exercisable will expire.

The options granted to employees are subject to the terms stipulated by section 102(b)(2) of the Israeli Income Tax Ordinance (the “Ordinance”). According to these provisions, the Company will not be allowed to claim as an expense for tax purposes the amounts credited to the employees as a capital gain benefit in respect of the options granted.

Options granted to related parties or non-employees of the Company are governed by Section 3(i) of the Ordinance or NSO. The Company will be allowed to claim as an expense for tax purposes in the year in which the related parties or non-employees exercised the options into shares.

As of December 31, 2020, 1,263,454 ordinary shares remain available for future grants under the Plan.

On January 4, 2021 the Company’s Board of Directors approved an increase of 1,052,896 ordinary shares that may be issued under the Company’s Plan.

share-based compensation grants to employees and directors:

On January 17, 2019, the Company granted options to purchase 124,000 ordinary shares to certain employees, with an exercise price of $3.97. The options vest over 4 years from the date of grant; 25% will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $341,000.

On January 17, 2019, the Company's Board of Directors approved to grant options to purchase 25,000 ordinary shares to the CMO, with an exercise price of $3.97. From the total options, 25% will vest on March 1, 2019 and the remaining 75% options shall vest in twelve equal quarterly installments over the next three years starting January 17, 2019. The grant was subject to the approval by the shareholders of the Company and was subsequently approved in May 2019. The fair value of the options at the date of grant was $68,000.

On January 17, 2019, the Company's Board of Directors approved to grant options to purchase 201,828 ordinary shares to non-executive directors of the Company, with an exercise price of $3.97. The options will vest over 3 years in twelve equal quarterly instalments starting in the vesting commencement date (as described in each agreement). The grant was subject to the approval by the shareholders of the Company and was subsequently approved in May 2019. The fair value of the options at the date of grant was $531,000.

On August 5, 2019, the Company’s Board of Directors approved to grant options to purchase 696,587 ordinary shares to the former CEO, with an exercise price of $2.75 per share. The options vest over 4 years from the date of grant. 25% will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date. The grant was subject to the approval by the shareholders of the Company and was subsequently approved in October 2019. The fair value of the options at the date of grant was $1.1 million. Effective September 7, 2020, upon the termination of the former CEO employment agreement, 522,440 of these options which have yet to fully vest are forfeited and were recognized as a reverse of expense under the General and Administrative line item in the amount of $314 thousand. In December 2020, the remaining of options were expired.

On November 18, 2019, the Company’s Board of Directors approved the following option grants:

Options grant to purchase 30,385 ordinary shares to the new US-based CFO, with an exercise price of $2.53 per share. The options will vest over two years in equal monthly installments following the grant date. The grant was subject to the approval by the shareholders of the Company and was subsequently approved in February 2020. The fair value of the options at the shareholders’ approval date was $59,797.

ii.

Options grant to purchase 33,638 ordinary shares t0 non-executive director of the Company, with an exercise price of $2.53. The options will vest over 3 years in twelve equal quarterly instalments starting on the vesting commencement date (as described in the agreement). The grant was subject to the approval by the shareholders of the Company and was subsequently approved in February 2020. The fair value of the options at the shareholders’ approval date was $68,856.

On March 16, 2020, options to purchase 201,600 ordinary shares to certain employees and 7,500 options granted to a service provider, with an exercise price of $2.14 per share. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $274,000.

On March 16, 2020, options to purchase 250,000 ordinary shares granted to certain executive officers of the Company, with an exercise price of $2.14. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $316,000.

On April 20, 2020 options to purchase 31,502 ordinary shares granted to the former CEO with an exercise price of $1.98 per share. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $37,000. Effective September 7, 2020, due to termination of the employment agreement with the former CEO, these options are forfeited and recognized as a reverse of expense under the General and Administrative line item in the amount of $4,000.

Share-based compensation to service provider:

In November 2019, the Board of Directors approved an option grant to a services provider in accordance with business development and advisory services agreement from August 2019. Under the terms of the agreement, the Company agreed to grant options to purchase the Company’s ordinary shares in an amount equal to $90,000 as of the date of grant, or 65,693 ordinary shares at an exercise price of $3.10. The options will vest over six months in equal monthly instalments starting in August 2019. See also Note 16d.

In April 2020, the Company entered into an investor relations services agreement. Under the terms of the agreement, the Company agreed to pay a monthly fee of $5,000 and to issue the consultant 28,000 Restricted Share Units (“RSU”), of which the first 7,000 shares vested on the signing date and the remaining 21,000 shares will vest in three equal installments until January 8, 2021. As of December 31, 2020, 21,000 shares were fully vested. The fair value of the RSU was $53,200 using the fair value of the shares at the grant date, of which $52,766 were recognized as an expense during the year ended December 31, 2020.

In November 2020, the Company entered into an amendment to business development services agreement with the business development consultant. Under the terms of the agreement, the Company agreed to pay a monthly fee of $5,000 and to issue the consultant 79,760 options with an exercise price of $1.06 per share. The options vests over 6 months in six equal installments from October 1, 2020. The fair value of the options at the date of grant was $35,094.

The fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:

	2020			2019			2018
Exercise price	$	1.06-$2.14		$	3.12		$	6.31
Dividend yield		-			-			-
Expected volatility		66.35%-71	%		71	%		68	%
Risk-free interest rate		0.16%-0.58	%		1.86	%		2.23	%
Expected life - in years		2.75-6.1			9.37			4.07

The fair value of each option with a par value exercise price is based on the fair value of ordinary share at the date of grant. The ordinary share price is derived from the value of equity and is based on market value, or prior to the IPO based on the valuation performed. The expected volatility is based on comparable companies. The risk-free interest rate is determined based on rates of return on maturity of unlinked treasury bonds with a time to maturity that equals the average life of the options.

Changes in the number of options and weighted average exercise prices are as follows:

	Year ended December 31,
	2020					2019					2018
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding at beginning of year		2,847,600		$	4.74		2,438,410		$	4.36		3,044,990		$	4.59
Expired		(226,106	)		2.68		(91,000	)		6.31		-			-
Forfeited		(589,793	)		2.7		(14,690	)		4.44		(718,120	)		5.73
Exercised (*)		(31,954	)		2.11		(662,251	)		0.21		(31,460	)		-
Granted		570,362		$	1.98		1,177,131		$	3.12		143,000		$	5.35
Outstanding at end of year		2,570,109		$	4.85		2,847,600		$	4.74		2,438,410		$	4.36
Exercisable at end of year		1,791,687		$	5.49		1,525,618		$	5.62		1,837,160		$	1.67

(*) The total intrinsic value of options exercised during the year ended December 31, 2020 was approximately $22,048.

The following is information about the exercise price and remaining contractual life of outstanding options at year-end:

December 31, 2020						December 31, 2019
Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life		Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life

	4,680		*		1.78		4,680		*		2.79
	79,760	$	1.06		4.85		-		-		-
	-		-		-		11,050	$	1.85		1.22
	-		-		-		65,000	$	2.11		0.05
	431,800	$	2.14		9.26		-		-		-
	64,023	$	2.53		8.89		64,023	$	2.53		9.89
	-		-		-		696,587	$	2.75		9.60
	65,693	$	3.10		3.89		65,693	$	3.10		4.89
	198,120	$	3.69		1.36		203,970	$	3.69		2.36
	332,953	$	3.97		7.91		340,828	$	3.97		9.05
	1,245,790	$	6.31		5.07		1,248,479	$	6.31		5.85
	147,290	$	7.54		2.26		147,290	$	7.54		3.26

Par value

The remaining unrecognized compensation expense as of December 31, 2020 is $0.5 million and will be expensed in full at April 2024.

Exercise of options

During 2019, current and former executive officers exercised 662,251 options into 662,251 ordinary shares for a total consideration of $138,000.

In January 2020, a consultant exercised 31,954 options into 31,954 ordinary shares for a total consideration of $68,000.

TAXES ON INCOME

12 Months Ended

Dec. 31, 2020

Major components of tax expense (income) [abstract]

TAXES ON INCOME

NOTE 11 - TAXES ON INCOME:

Entera Bio Ltd.

The Company is taxed according to Israeli tax laws:

Measurement of results for tax purposes

The Company measures its results for tax purposes in nominal terms in NIS based on financial reporting under Israeli accounting principles, while (as detailed in note 2) the functional currency of the Company is the U.S. dollar and the Company’s financial statements are measured in U.S. dollars and in accordance with IFRS. Therefore, there are differences between the Company’s taxable income (loss) and income (loss) reflected in these financial statements.

Tax rates

The income of the Company is subject to the Israel corporate tax rates of 23%.

Capital gains are subject to capital gain tax according to the corporate tax rate for the year during which the assets are sold.

Entera Bio Inc.

Entera Bio Inc. is taxed according to U.S. tax laws. The Company’s income is taxed in the United States at the rate of 28%.

Taxes on income included in the consolidated statements of comprehensive loss represent current taxes due to taxable income of the Company's subsidiary.

Losses for tax purposes carried forward to future years

Entera Bio Ltd.

The balance of carryforward losses as of December 31, 2020 and 2019 are approximately $43 million and $30 million, respectively.

Under Israeli tax law, tax loss carry forward have no expiration date.

Deferred tax assets on losses for tax purposes carried forward to subsequent years are recognized if utilization of the related tax benefit against a future taxable income is expected. The Company has not created deferred tax assets based on its carry forward losses and other temporary assets since their utilization is not expected in the foreseeable future.

Reconciliation of the theoretical tax expense to actual tax expense

The main reconciling item between the statutory tax rate of the Company and the effective rate is unrecognized tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).

Tax assessments

In accordance with the Income Tax Ordinance, as of December 31, 2020, all of the Company's tax assessments through tax year 2015 are considered final.

REVENUE FROM COLLABORATION AND LICENSE AGREEMENT	12 Months Ended
REVENUE FROM COLLABORATION AND LICENSE AGREEMENT	Dec. 31, 2020
Receivables from contracts with customers [abstract]
REVENUE FROM COLLABORATION AND LICENSE AGREEMENT	NOTE 12 - REVENUE FROM COLLABORATION AND LICENSE AGREEMENT On December 10, 2018, the Company entered into a research collaboration and license agreement (the “Amgen Agreement”) with Amgen Inc. (“Amgen”) in inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement, the Company and Amgen will use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has options to select up to two additional programs to include in the collaboration. Amgen is responsible for the clinical development, regulatory approval, manufacturing and worldwide commercialization of the programs. The Company granted Amgen an exclusive, worldwide, sublicensable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed through the performance of the collaboration is to be determined by U.S. patent law. Pursuant to the terms of the Amgen Agreement, Amgen is required to make aggregate payments of up to $270 million upon achievement of various clinical and commercial milestones or its exercise of options to select additional two programs to include in the collaboration, as well as tiered royalty payments ranging from the low to mid-single digits based on the level of Amgen’s net sales of the applicable products. Amgen is required to pay for the initial program $450 thousand for the second year of preclinical R&D services to be provided by the Company and must reimburse the Company for further expenses as shall be agreed between the parties. Preclinical R&D services includes time spent by the Company's employees performing the Company's activities under the work plan of collaboration program Amgen’s obligation to pay royalties with respect to a product in a particular country commences upon the first commercial sale of such product in such country and expires on a country-by-country and product-by-product basis on the later of (a) the date on which the sale of the product is no longer covered by a valid claim of a patent licensed to Amgen under the Amgen Agreement, and (b) the tenth anniversary of the first commercial sale of such product in such country. The term of the Amgen Agreement commenced on December 10, 2018, and unless earlier terminated, shall continue in full force and effect, on a product-by-product basis, until expiration of the last-to-expire royalty term with respect to such product. In January 2019, as required by the Amgen Agreement, Amgen paid the Company a non-refundable and non-creditable initial technology access fee of $725 thousand. The Company evaluated the selling price of the preclinical R&D services at $225 thousand and the right to use the intellectual property (“License fees”) at $500 thousand. In December 2018, the Company recognized $500 thousand in revenues for the right to use the intellectual property. Revenues attributed to the preclinical R&D services are recognized during the period of the pre-clinical R&D services according to the input model method on a cost-to-cost basis. In January 2020 and 2021, the Company received the first and second installments of the second year pre-clinical R&D services in the amount of $450 thousands. During 2020 and 2019, the Company recorded revenues of $365 thousand and $236 thousand related to services provided under the Amgen Agreement. In addition, as of December 31, 2020 and 2019 the Company recorded a contract liability of $143 thousand and $267 thousand, respectively.

SUPPLEMENTARY FINANCIAL INFORMATION

12 Months Ended

Dec. 31, 2020

Disclosure of supplementary financial information [abstract]

SUPPLEMENTARY FINANCIAL INFORMATION

NOTE 13 - SUPPLEMENTARY FINANCIAL INFORMATION:

	December 31,
	2020		2019
	U.S. dollars in thousands
a. Other current assets:
Prepaid expenses		98		39
Restricted deposits		70		37
Other		93		97
		261		173


	December 31,
	2020		2019
	U.S. dollars in thousands
b. Accounts payable - other:
Employees and employees related		144		345
Provision for vacation		263		231
Accrued expenses and other		923		794
		1,330		1,370

BASIC AND DILUTED LOSS PER SHARE

12 Months Ended

Dec. 31, 2020

Basic and diluted earnings per share [abstract]

BASIC AND DILUTED LOSS PER SHARE

NOTE 14 - BASIC AND DILUTED LOSS PER SHARE:

Basic

Basic loss per share is calculated by dividing the result attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year.

Diluted

Warrants to issue ordinary shares and all options, have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2020 since their effect was anti-dilutive. The total number of shares related to the outstanding warrants to issue ordinary shares and options excluded from the calculation of diluted loss per share was 7,072,384 for the year ended December 31, 2020.

Warrants to issue ordinary shares and all options, have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2019 since their effect was anti-dilutive. The total number of shares related to the outstanding warrants to issue ordinary shares and options excluded from the calculation of diluted loss per share was 4,849,855 for the year ended December 31, 2019.

The 2012 Convertible Loan, preferred shares, warrants to issue preferred shares A, warrants to issue preferred shares B up to the closing of the IPO and warrants to issue ordinary shares and all options, have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2018 since their effect was anti-dilutive. The total number of shares related to the outstanding options, the 2012 Convertible Loan, preferred shares, warrants to issue preferred shares A, warrants to issue preferred shares B and warrants to issue ordinary shares and excluded from the calculation of diluted loss per share was 10,596,130 for the year ended December 31, 2018.

	Year ended December 31,
	2020		2019		2018
	U.S. dollars in thousand (except for share numbers)

Loss attributable to equity holders of the Company		9,983		10,795		10,304
Income from change in fair value of financial liabilities at fair value		155		-		135
Loss used for the computation of diluted loss per share		10,138		10,795		10,439
Weighted average number of ordinary shares used in
the computation of basic loss per share		18,417,093		12,146,729		7,955,447
Add:
Weighted average number of additional shares issuable upon the assumed conversion/exercise of preferred shares and warrants to issue preferred shares and shares		146,582		-		27,955
Weighted average number of ordinary shares used in the computation of diluted loss per share
		18,563,675		12,146,729		7,983,402

Basic loss per ordinary share		0.54		0.89		1.30
Diluted loss per ordinary share		0.55		0.89		1.31

RELATED PARTIES - TRANSACTIONS AND BALANCES

12 Months Ended

Dec. 31, 2020

Disclosure of transactions between related parties [abstract]

NOTE 15 - RELATED PARTIES - TRANSACTIONS AND BALANCES:

Transactions with related parties:

Key management personnel include members of the Board of Directors, the Chief Executive Officer, President of R&D, Chief Operating Officer, Chief Medical Officer, and Chief Financial Officer.

The Company granted stock options to certain key management personnel and directors, see note 10j.

Key management compensation:

	Year ended December 31,
	2020		2019		2018
	U.S. dollars in thousands

Labor cost and related expenses		2,065		1,537		1,180
Share-based compensation		599		1,146		868
Directors fee and services		472		415		429
Others		32		23		30
		3,168		3,121		2,507

Balances with related parties:

	December 31,
	2020		2019
	U.S. dollars in thousands
Key management:
Payables and accrued expenses		87		244
Severance pay obligations		81		70
Provision for vacation		201		194
Directors fee and services		105		106

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2020

Disclosure of non-adjusting events after reporting period [abstract]

SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS

On January 4, 2021 options to purchase 1,314,218 ordinary shares were granted to the Chief Executive officer of the Company, with an exercise price of $1.24. The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% of the option will vest in twelve equal quarterly installments following the first anniversary of the grant date. The grant was subject to the approval by the shareholders of the Company and was subsequently approved in March 2021.

In February and March 2021, the Company issued additional 2,546,265 ordinary shares for net proceeds of $9.8 million at a weighted average price of $3.99 per ordinary share through the Company’s ATM Program. See also as described in note 10i.

In February 2021, one of the Investor Warrant’s holders exercised 142,406 warrant into 56,075 ordinary shares through cashless exercise mechanism.

In March 2021, a service provider exercised 65,693 options into 65,693 ordinary shares of the Company for a total consideration of $204 thousand at an exercise price of $3.10. See also as described in note 10j.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2020

Disclosure of summary of significant accounting policies [abstract]

Basis of preparation of the financial statements

a.	Basis of preparation of the financial statements:

The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated.

The financial statements have been prepared under the historical cost except for financial liabilities at fair value through profit or loss.

Functional and presentation currency

b.	Functional and presentation currency:

Functional and presentation currency

Transactions and balances

Basis of consolidation

c.	Basis of consolidation The consolidated financial statements include the accounts of the Company and its subsidiary, Entera Bio Inc. Intercompany transactions and balances have been eliminated upon consolidation.

Cash and cash equivalents

d.	Cash and cash equivalents Cash and cash equivalents include cash on hand and short-term bank deposits (with original maturities of three months or less) that are not restricted as to withdrawal or use and are therefore considered to be cash equivalents.

Short-term bank deposits

e.	Short-term bank deposits Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. The fair value of short-term bank deposits approximates their carrying value, since they bear interest at rates close to the prevailing market rates.

Restricted deposits

f.	Restricted deposits Restricted deposits relate to accounts where withdrawals are restricted under contractual agreements.

Property and equipment

g.	Property and equipment

The assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives, as follows:

	Years
Compute equipment		3-5
Office furniture		5
Lab equipment		7-10
Leasehold improvements*		3-5

*Leasehold improvements are depreciated over the lease period or the expected useful life of the improvements, whichever is shorter.

Intangible assets

h.	Intangible assets:

Research and development expenses

Research expenses are charged to profit or loss as incurred. An intangible asset arising from development of the Company's products is recognized if all of the following conditions are met:

•

It is technically feasible to complete the intangible asset so that it will be available for use;

•

Management intends to complete the intangible asset and use it or sell it;

•

There is an ability to use or sell the intangible asset;

•

It can be demonstrated how the intangible asset will generate probable future economic benefits;

•

As of December 31, 2020, the Company has not capitalized development costs.

In process research and development (IPR&D)

IPR&D acquired is presented based on the fair value at the date of the acquisition and tested annually for impairment.

Impairment of non-financial assets

i.	Impairment of non-financial assets

For the years ended December 31, 2020 and 2019, no impairment has been recognized.

Leases

Payments associated with short-term leases (leases with a lease term of 12 months or less) and leases of low-value assets are recognized on a straight-line basis as an expense in profit or loss.

See also note 9.

Segment reporting

k.	Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment.

Financial instruments

l.	Financial instruments Accounts receivables are classified at amortized cost. This category is subject to an impairment test under the expected credit losses model in accordance with IFRS 9.

Warrants

Share capital

n.	Share capital Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are included in equity as a deduction from the proceeds.

Deferred income tax

In the absence of expectation of taxable income in the future, no deferred tax assets are recorded in the financial statements.

Share-based payments

When options are exercised, the Company issues new shares, with proceeds less directly attributable transaction costs recognized as share capital (par value) and additional paid in capital.

Revenue recognition

Revenue recognition:

In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:

Identification of the contract, or contracts, with a customer.

Identification of the performance obligations in the contract.

Determination of the transaction price.

Allocation of the transaction price to the performance obligations in the contract.

Recognition of revenue.

Revenues attributed to the preclinical R&Ds services are recognized during the period of the pre-clinical R&D services, over time according to the input model method on a cost-to-cost basis.

An entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

The subsequent sale or usage occurs; and

The performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially satisfied).

Government grants

Loss per ordinary share

Recently Issued Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure of summary of significant accounting policies [abstract]

Schedule of Estimated Useful Lives of Assets

The assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives, as follows:

	Years
Compute equipment		3-5
Office furniture		5
Lab equipment		7-10
Leasehold improvements*		3-5

*Leasehold improvements are depreciated over the lease period or the expected useful life of the improvements, whichever is shorter.

FINANCIAL INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure of detailed information about financial instruments [abstract]

Schedule of Classification of Financial Instruments by Groups

Classification of financial instruments by groups:


	Financial liabilities at fair value through profit or loss		Financial liabilities at amortized cost		Total
	U.S. dollars in thousands

As of December 31, 2020:
Trade and other payable		-		1,494		1,494
Warrants to purchase ordinary shares (Level 1) (1)		239		-		239
Warrants to purchase ordinary shares (Level 3) (2)		1,193		-		1,193
Lease liabilities				432		432
		1,432		1,926		3,358

As of December 31, 2019:
Trade and other payable		-		1,704		1,704
Warrants to purchase ordinary shares (Level 1) (1)		266		-		266
Warrants to purchase ordinary shares (Level 3) (2)		2,178		-		2,178
Lease liabilities		-		299		299
		2,444		2,003		4,447

(1) Tradable warrants presented above are valuated based on the market price (a Level 1 valuation).

(2) Warrants to purchase ordinary shares issued in December 2019 and February 2020 are valuated based on the Monte-Carlo pricing model (a Level 3 valuation).

Schedule of Assumptions

The main assumptions used are as follows:

	December 31			December 31
	2020			2019
Price per share	$	1.08		$	1.84-$2.07
Volatility		66	%		62%-63	%
Expected term		2			3
Risk free interest rate		0.1%-0.13	%		1.63%-1.71	%
Expected dividend		0	%		0	%

LEASES (Tables)

12 Months Ended

Dec. 31, 2020

Presentation of leases for lessee [abstract]

Schedule of Composition of Right-of-Use Assets

The Following table is the composition of right-of-use assets by type:

	As of December 31, 2020		As of December 31, 2019		As of January 1, 2019
Facility		306		253		151
Vehicles		50		7		15
Total right-of-use asset		356		260		166

Schedule of Summarize Contractual Obligations

The following table summarize the contractual obligations:

	Payments due by period
	Total		Less than 1 year		1 - 3 years
	(In thousands)
Operating leases for facility and vehicles as of December 31, 2019	$	346	$	177	$	169
Operating leases for facility and vehicles as of December 31, 2020	$	510	$	205	$	305

Schedule of Leases

	Year ended December 31,
	2020		2019

Depreciation expense:
Facility		137		121
Vehicles		7		9
Financial expense		33		55
Cash paid for amounts included in the measurement of lease liabilities		179		169
Right of use assets obtained in exchange for expanded period of operating lease liabilities		258		224

SHARE CAPITAL (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure of classes of share capital [abstract]

Schedule of Composition of Ordinary Shares

The share capital composed of ordinary shares of NIS 0.0000769 par value, as follows:

	Number of ordinary shares
	December 31
	2020		2019
Authorized		140,010,000		140,010,000
Issued		21,057,922		17,864,684

Schedule of Weighted Average Assumptions

The fair value of each option granted is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:

	2020			2019			2018
Exercise price	$	1.06-$2.14		$	3.12		$	6.31
Dividend yield		-			-			-
Expected volatility		66.35%-71	%		71	%		68	%
Risk-free interest rate		0.16%-0.58	%		1.86	%		2.23	%
Expected life - in years		2.75-6.1			9.37			4.07

Schedule of Changes in Number of Options and Weighted Average Exercise Prices

maturity of unlinked treasury bonds with a time to maturity that equals the average life of the options.

Changes in the number of options and weighted average exercise prices are as follows:

	Year ended December 31,
	2020					2019					2018
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options			Weighted average exercise price
Outstanding at beginning of year		2,847,600		$	4.74		2,438,410		$	4.36		3,044,990		$	4.59
Expired		(226,106	)		2.68		(91,000	)		6.31		-			-
Forfeited		(589,793	)		2.7		(14,690	)		4.44		(718,120	)		5.73
Exercised (*)		(31,954	)		2.11		(662,251	)		0.21		(31,460	)		-
Granted		570,362		$	1.98		1,177,131		$	3.12		143,000		$	5.35
Outstanding at end of year		2,570,109		$	4.85		2,847,600		$	4.74		2,438,410		$	4.36
Exercisable at end of year		1,791,687		$	5.49		1,525,618		$	5.62		1,837,160		$	1.67

(*) The total intrinsic value of options exercised during the year ended December 31, 2020 was approximately $22,048.

Schedule of Information about Exercise Price and Remaining Contractual Life of Outstanding Options

The following is information about the exercise price and remaining contractual life of outstanding options at year-end:

December 31, 2020						December 31, 2019
Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life		Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life

	4,680		*		1.78		4,680		*		2.79
	79,760	$	1.06		4.85		-		-		-
	-		-		-		11,050	$	1.85		1.22
	-		-		-		65,000	$	2.11		0.05
	431,800	$	2.14		9.26		-		-		-
	64,023	$	2.53		8.89		64,023	$	2.53		9.89
	-		-		-		696,587	$	2.75		9.60
	65,693	$	3.10		3.89		65,693	$	3.10		4.89
	198,120	$	3.69		1.36		203,970	$	3.69		2.36
	332,953	$	3.97		7.91		340,828	$	3.97		9.05
	1,245,790	$	6.31		5.07		1,248,479	$	6.31		5.85
	147,290	$	7.54		2.26		147,290	$	7.54		3.26

Par value

SUPPLEMENTARY FINANCIAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure of supplementary financial information [abstract]

Schedule of Other Current Assets

	December 31,
	2020		2019
	U.S. dollars in thousands
a. Other current assets:
Prepaid expenses		98		39
Restricted deposits		70		37
Other		93		97
		261		173

Schedule of Accounts Payable Other

	December 31,
	2020		2019
	U.S. dollars in thousands
b. Accounts payable - other:
Employees and employees related		144		345
Provision for vacation		263		231
Accrued expenses and other		923		794
		1,330		1,370

BASIC AND DILUTED LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2020

Basic and diluted earnings per share [abstract]

Schedule of Basic and Diluted Loss Per Share

The total number of shares related to the outstanding options, the 2012 Convertible Loan, preferred shares, warrants to issue preferred shares A, warrants to issue preferred shares B and warrants to issue ordinary shares and excluded from the calculation of diluted loss per share was 10,596,130 for the year ended December 31, 2018.

	Year ended December 31,
	2020		2019		2018
	U.S. dollars in thousand (except for share numbers)

Loss attributable to equity holders of the Company		9,983		10,795		10,304
Income from change in fair value of financial liabilities at fair value		155		-		135
Loss used for the computation of diluted loss per share		10,138		10,795		10,439
Weighted average number of ordinary shares used in
the computation of basic loss per share		18,417,093		12,146,729		7,955,447
Add:
Weighted average number of additional shares issuable upon the assumed conversion/exercise of preferred shares and warrants to issue preferred shares and shares		146,582		-		27,955
Weighted average number of ordinary shares used in the computation of diluted loss per share
		18,563,675		12,146,729		7,983,402

Basic loss per ordinary share		0.54		0.89		1.30
Diluted loss per ordinary share		0.55		0.89		1.31

RELATED PARTIES - TRANSACTIONS AND BALANCES (Tables)

12 Months Ended

Dec. 31, 2020

Disclosure of transactions between related parties [abstract]

Schedule of Transactions with Related Parties

Key management compensation:

	Year ended December 31,
	2020		2019		2018
	U.S. dollars in thousands

Labor cost and related expenses		2,065		1,537		1,180
Share-based compensation		599		1,146		868
Directors fee and services		472		415		429
Others		32		23		30
		3,168		3,121		2,507

Schedule of Balances with Related Parties

Balances with related parties:

	December 31,
	2020		2019
	U.S. dollars in thousands
Key management:
Payables and accrued expenses		87		244
Severance pay obligations		81		70
Provision for vacation		201		194
Directors fee and services		105		106

GENERAL INFORMATION (Details) - USD ($) $ in Thousands	1 Months Ended
GENERAL INFORMATION (Details) - USD ($) $ in Thousands	Jul. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Statement Line Items [Line Items]
Accumulated losses		$ 72,895	$ 62,912
Number of shares issued		21,057,922	17,864,684
IPO [Member]
Statement Line Items [Line Items]
Number of shares issued	1,400,000
Net proceeds from issuing shares	$ 9,600

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Statement Line Items [Line Items]
Revenue from contract with customer		$ 365	$ 236	$ 500
Amgen Inc [Member]
Statement Line Items [Line Items]
Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services		225
Revenue from contract with customer		$ 500
Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services	$ 725

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2020-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Estimated Useful Lives of Assets) (Details)

12 Months Ended

Dec. 31, 2020

Computers equipment [Member] | Bottom of range [Member]

Disclosure of detailed information about property, plant and equipment [line items]

Computers equipment [Member] | Top of range [Member]

3 years

Disclosure of detailed information about property, plant and equipment [line items]

Office furniture [Member]

5 years

Disclosure of detailed information about property, plant and equipment [line items]

Lab equipment [Member] | Bottom of range [Member]

5 years

Disclosure of detailed information about property, plant and equipment [line items]

Lab equipment [Member] | Top of range [Member]

7 years

Disclosure of detailed information about property, plant and equipment [line items]

Leasehold improvements [Member] | Bottom of range [Member]

10 years

Disclosure of detailed information about property, plant and equipment [line items]

Leasehold improvements [Member] | Top of range [Member]

3 years

^[1]

Disclosure of detailed information about property, plant and equipment [line items]

Disclosure of detailed information about financial instruments [line items]

5 years

^[1]

[1]	Leasehold improvements are depreciated over the lease period or the expected useful life of the improvements, whichever is shorter.

FINANCIAL INSTRUMENTS (Schedule of Classification of Financial Instruments by Groups - Liabilities) (Details) - USD ($)
$ in Thousands

Dec. 31, 2020

Dec. 31, 2019

Trade and other payable

$ 1,494

$ 1,704

Warrants to purchase ordinary shares (Level 1)

^[1]

239

266

Warrants to purchase ordinary shares (Level 3)

^[2]

1,193

2,178

Financial liabilities at fair value through profit or loss [Member]

432

299

Financial liabilities

3,358

4,447

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

Warrants to purchase ordinary shares (Level 1)

^[1]

239

266

Warrants to purchase ordinary shares (Level 3)

^[2]

1,193

2,178

Financial liabilities at amortized cost [Member]

Financial liabilities

1,432

2,444

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

1,494

1,704

Warrants to purchase ordinary shares (Level 1)

^[1]

Warrants to purchase ordinary shares (Level 3)

^[2]

Disclosure of classes of share capital [line items]

432

299

Financial liabilities

$ 1,926

$ 2,003

[1]	Tradable warrants presented above are valuated based on the market price (a Level 1 valuation).
[2]	Warrants to purchase ordinary shares issued in December 2019 and February 2020 are valuated based on the Monte-Carlo pricing model (a Level 3 valuation).

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

FINANCIAL INSTRUMENTS (Schedule of Assumptions) (Details) - Financial Instruments [Member] - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about financial instruments [line items]
Price per share	$ 1.08
Volatility	66.00%
Expected term	2 years	3 years
Expected dividend	0.00%	0.00%
Bottom of range [Member]
Disclosure of detailed information about financial instruments [line items]
Price per share		$ 1.84
Volatility		62.00%
Risk free interest rate	0.10%	1.63%
Top of range [Member]
Disclosure of detailed information about financial instruments [line items]
Price per share		$ 2.07
Volatility		63.00%
Risk free interest rate	0.13%	1.71%

INTANGIBLE ASSETS (Details) - USD ($)	Jun. 01, 2010	Feb. 22, 2011
D.N.A. and Oramed [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of ordinary shares	50.00%
D.N.A. Biomedical Solutions Ltd. [Member]
Disclosure of detailed information about intangible assets [line items]
Amount invested in joint venture	$ 600,000
Oramed [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of royalties to be paid		3.00%

CONVERTIBLE LOANS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended							60 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2012	Dec. 31, 2016
Disclosure of detailed information about borrowings [line items]
Conversion of convertible loan into Ordinary shares			$ 4,138
2012 Convertible Loan, 2016 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings							$ 12,400
Maturity								Each of the loans bears interest at a rate between 0.6% to 5% per year, which is to be repaid as described in each agreement.
2012 Convertible Loan, 2016 Convertible Loan [Member] \| Bottom of range [Member]
Disclosure of detailed information about borrowings [line items]
Interest rate							0.60%
2012 Convertible Loan, 2016 Convertible Loan [Member] \| Top of range [Member]
Disclosure of detailed information about borrowings [line items]
Interest rate							5.00%
2012 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Convertible loan converted into ordinary shares			622,180				622,180
Conversion of convertible loan into Ordinary shares							$ 4,100
2015 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings						$ 2,000
Percentage of warrants to purchase additional shares on conversion						40.00%
Repayments of borrowings				$ 900
2016 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings					$ 7,400			$ 7,400
Conversion price per share					$ 5.24
Exercisable period of warrants					4 years
Convertible loan and accrued interest converted into series B-1 preferred shares					1,719,770
Exercise price of warrants					$ 6.99
Percentage of warrants to purchase additional shares on conversion					40.00%
Repayments of borrowings				$ 1,100

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES (Narrative) (Details)
$ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

12 Months Ended

Jun. 13, 2020

Jul. 02, 2018

USD ($)

Jul. 31, 2020

Dec. 31, 2017

USD ($)

$ / shares

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2016

$ / shares

570,362

1,177,131

143,000

2016 Convertible Loan [Member]

^[1]

31,954

662,251

31,460

Disclosure of classes of share capital [line items]

Series A preferred shares [Member]

$ 6.99

Disclosure of classes of share capital [line items]

Proceeds from issue of preferred shares | $

$ 5,000

Warrants issued to purchase preferred shares

332,020

Number of warrants converted into additional warrants to purchase ordinary shares

2,554

Number of preferred shares converted to ordinary shares following closing of IPO

10,222

340,210

Series A preferred shares [Member] | Investors [Member]

1,328,860

Disclosure of classes of share capital [line items]

Warrants to series A preferred shares [Member]

387,530

Disclosure of classes of share capital [line items]

Warrants to series A preferred shares [Member] | Investors [Member]

332,020

Disclosure of classes of share capital [line items]

Series B preferred shares [Member]

85,931

96,980

Disclosure of classes of share capital [line items]

$ 908.78

687,960

Series B preferred shares [Member] | Investors [Member]

1,856,790

Disclosure of classes of share capital [line items]

Warrants issued to purchase preferred shares

14,283

Total consideration net of issuance costs | $

$ 12,100

Series B preferred shares [Member] | Broker dealer [Member]

Disclosure of classes of share capital [line items]

Preferred shares, price per share | $ / shares

$ 908.78

Warrants issued to purchase preferred shares

526

Additional issuance costs | $

$ 198

Preferred Shares Series B- 1 [Member] | 2016 Convertible Loan [Member]

Disclosure of classes of share capital [line items]

Shares issued in conversion of debt

13,229

Shares issued in conversion of debt, value | $

$ 9,000

Shares issued in conversion of debt, price per share | $ / shares

$ 681.585

Series B-1 preferred shares [Member]

Disclosure of classes of share capital [line items]

Warrants to series B preferred shares [Member]

1,719,770

Disclosure of classes of share capital [line items]

Warrants to series B-1 preferred shares [Member]

756,340

Disclosure of classes of share capital [line items]

Disclosure of classes of share capital [line items]

467,220

[1]	The total intrinsic value of options exercised during the year ended December 31, 2020 was approximately $22,048.

COMMITMENTS (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
COMMITMENTS (Details) - USD ($) $ in Thousands	Jan. 31, 2021	Dec. 31, 2020
Statement Line Items [Line Items]
Percentage of royalty payable on sales of products developed during first three years		3.00%
Percentage of royalty payable on sales of products developed during subsequent three years		4.00%
Percentage of royalty payable on sales of products developed during commencing of seventh year		5.00%
Percentage of royalty payable on grants received by company		100.00%
Royalty amount payable		$ 460
Percentage to be paid for each payment received		5.38%
Amgen Inc [Member]
Statement Line Items [Line Items]
Amount paid to government of israel	$ 13	$ 54

LEASES (Narrative) (Details)	12 Months Ended
LEASES (Narrative) (Details)	Dec. 31, 2020 USD ($)
Disclosure of quantitative information about right-of-use assets [line items]
Bank guarantees	$ 25,000
Buildings [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Annual lease consideration total amount	$ 164,000
Lease expiration date	Jun. 30, 2023
Leases [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Borrowings rate	16.00%

LEASES (Schedule of Composition of Right-of-Use Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	$ 356	$ 260
Initial Application of IFRS 16 [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset		166
Facility [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	306	253
Facility [Member] \| Initial Application of IFRS 16 [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset		151
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset	$ 50	7
Vehicles [Member] \| Initial Application of IFRS 16 [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Total right-of-use asset		$ 15

LEASES (Schedule of Summarize Contractual Obligations) (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles	$ 510	$ 346
Less than 1 year [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles	205	177
1-3 years [Member]
Disclosure of maturity analysis of operating lease payments [line items]
Operating leases for facility and vehicles	$ 305	$ 169

LEASES (Schedule of Leases) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of quantitative information about right-of-use assets [line items]
Financial expense	$ 33	$ 55
Cash paid for amounts included in the measurement of lease liabilities	179	169
Right of use assets obtained in exchange for expanded period of operating lease liabilities	258	224
Facility [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation expense:	137	121
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Depreciation expense:	$ 7	$ 9

SHARE CAPITAL (Narrative) (Details)

1 Months Ended

3 Months Ended

7 Months Ended

12 Months Ended

Jan. 08, 2021

Sep. 07, 2020

USD ($)

Jul. 04, 2020

USD ($)

Jun. 13, 2020

USD ($)

$ / shares

Dec. 13, 2019

USD ($)

$ / shares

Oct. 04, 2019

USD ($)

$ / shares

Aug. 05, 2019

USD ($)

$ / shares

Jul. 02, 2018

USD ($)

$ / shares

Nov. 30, 2020

USD ($)

$ / shares

Jul. 31, 2020

USD ($)

$ / shares

Apr. 30, 2020

USD ($)

Apr. 20, 2020

USD ($)

$ / shares

Mar. 16, 2020

USD ($)

$ / shares

Jan. 31, 2020

USD ($)

Dec. 31, 2019

USD ($)

$ / shares

Nov. 30, 2019

USD ($)

$ / shares

Nov. 18, 2019

USD ($)

$ / shares

Jan. 17, 2019

USD ($)

$ / shares

Jul. 26, 2018

USD ($)

Jan. 30, 2018

USD ($)

Dec. 31, 2017

$ / shares

Jul. 20, 2019

USD ($)

Dec. 31, 2020

USD ($)

$ / shares

Dec. 31, 2019

USD ($)

$ / shares

Dec. 31, 2018

$ / shares

Dec. 31, 2016

$ / shares

Dec. 31, 2012

Jan. 04, 2021

Dec. 31, 2020

₪ / shares

Dec. 31, 2019

₪ / shares

Mar. 17, 2013

₪ / shares

Stock split

1-for- 130

Ordinary shares remain available for future grants

17,864,684

21,057,922

17,864,684

1,263,454

Percentage of aggregate purchase price paid in cash by purchasers equal to per month

1.00%

Par value per share | ₪ / shares

₪ 0.0000769

570,362

1,177,131

143,000

$ 1.98

$ 3.12

$ 5.35

Remaining unrecognized compensation expense | $

$ 274,000

$ 500,000

Transaction costs | $

$ 1,200,000

Capital stock price per share | $ / shares

$ 2.37

Reserved ordinary shares

1,371,398

Transfer from other reserves to additional paid in capital | $

^[1]

31,954

662,251

31,460

$ 1,400,000

Number of options forfieted

589,793

14,690

718,120

D.N.A. Placement [Member]

Disclosure of classes of share capital [line items]

Proceeds from private placement | $

337,553

$ 800,000

168,776

$ 2.96

Under Company Plan [Member]

Exercisable over a three-year period from the date of issuance

Disclosure of classes of share capital [line items]

Increase of ordinary shares remain available for future grants

1,052,896

2012 Convertible Loan [Member]

Disclosure of classes of share capital [line items]

Convertible loan converted into ordinary shares

622,180

2016 Convertible Loan [Member]

Disclosure of classes of share capital [line items]

$ 6.99

467,220

Transfer from other reserves to additional paid in capital | $

$ 5.24

$ 1,200,000

IPO [Member]

Disclosure of classes of share capital [line items]

IPO [Member] | Underwriters [Member]

1,400,000

Disclosure of classes of share capital [line items]

Warrants issued to purchase shares

10,000

70,000

Stock issuance costs | $

$ 255,000

Fair value of warrants | $

$ 8.80

$ 66,500

Warrants [Member]

Disclosure of classes of share capital [line items]

1,400,000

Adjusted exercise price of warrants | $ / shares

$ 8.4

Warrant term

five years

$ 5.85

Exceeds sales price per share | $ / shares

$ 24.00

Percentage of per unit price

300.00%

Warrants [Member] | Underwriters [Member]

443,950

Disclosure of classes of share capital [line items]

Warrants converted into ordinary shares

105,000

Proceeds from issuance of ordinary shares, net | $

$ 2,100

Fair value of warrants | $

210,000

$ 172,000

Ordinary shares [member]

Disclosure of classes of share capital [line items]

Warrants issued to purchase shares

700,000

Proceeds from issuance of ordinary shares, net | $

$ 9,600,000

Proceeds from issuance of ordinary shares, gross | $

11,200,000

Underwriters fee | $

900,000

Other issuance costs | $

$ 700,000

Public offering price per unit | $ / shares

$ 8.0

Number of ordinary shares that can be purchased through each tradeable warrant

0.5

Series A preferred shares [Member]

443,950

Disclosure of classes of share capital [line items]

1,328,860

340,210

340,210

Transfer from other reserves to additional paid in capital | $

$ 3.69

$ 1,200,000

Series A preferred shares [Member] | Investors [Member]

Disclosure of classes of share capital [line items]

Series B preferred shares [Member]

387,530

Disclosure of classes of share capital [line items]

$ 908.78

1,856,790

687,960

687,960

Transfer from other reserves to additional paid in capital | $

$ 6.99

$ 1,500,000

Series B-1 preferred shares [Member]

Disclosure of classes of share capital [line items]

Warrants to series A preferred shares [Member]

1,719,770

Disclosure of classes of share capital [line items]

Warrants to series A preferred shares [Member] | Investors [Member]

332,020

Disclosure of classes of share capital [line items]

Warrants to series B preferred shares [Member]

85,931

96,980

Disclosure of classes of share capital [line items]

Warrants to series B-1 preferred shares [Member]

756,340

Disclosure of classes of share capital [line items]

Broker Warrants type 1 [Member]

467,220

Disclosure of classes of share capital [line items]

Broker Warrants type 2 [Member]

184,515

Disclosure of classes of share capital [line items]

Disclosure of classes of share capital [line items]

92,257

ATM Program [Member]

Proceeds from issuance of ordinary shares, net | $

2,802,731

$ 13,900,000

$ 3,200,000

Proceeds from issuance of ordinary shares, gross | $

$ 3,500,000

Capital stock price per share | $ / shares

$ 1.05

2.37

Weighted average price | $ / shares

$ 1.27

Share-based Compensation Expense [member]

Disclosure of classes of share capital [line items]

Transaction costs | $

$ 205,000

Certain Consultant [Member]

Disclosure of classes of share capital [line items]

32,500

Value of options exercised | $

8,190

$ 100,000

Options granted to services providers [Member]

Disclosure of classes of share capital [line items]

65,693

$ 3.10

The options will vest over six months in equal monthly instalments starting in August 2019.

New US-based CFO [Member]

$ 90,000

Disclosure of classes of share capital [line items]

30,385

$ 2.53

The options will vest over two years in equal monthly installments following the grant date.

Non-executive director [Member]

$ 59,797

Disclosure of classes of share capital [line items]

33,638

201,828

$ 2.53

$ 3.97

The options will vest over 3 years in twelve equal quarterly instalments starting on the vesting commencement date (as described in the agreement).

The options will vest over 3 years in twelve equal quarterly instalments starting in the vesting commencement date (as described in each agreement).

Certain employees [Member]

$ 68,856

$ 531,000

Disclosure of classes of share capital [line items]

201,600

124,000

$ 2.14

$ 3.97

The options vest over 4 years from the date of grant; 25% vest on the first anniversary of the date of grant and the remaining 75% vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.

The options vest over 4 years from the date of grant; 25% will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date.

Disclosure of classes of share capital [line items]

$ 341,000

CMO [Member]

25,000

$ 3.97

From the total options, 25% will vest on March 1, 2019 and the remaining 75% options shall vest in twelve equal quarterly installments over the next three years starting January 17, 2019.

Disclosure of classes of share capital [line items]

$ 68,000

New CEO [Member]

696,587

$ 2.75

The options vest over 4 years from the date of grant. 25% will vest on the first anniversary of the date of grant and the remaining 75% options shall vest in twelve equal quarterly installments following the first anniversary of the grant date.

Number of options forfieted

$ 1,100,000

522,440

General and administrative expenses reversal | $

$ 314,000

Certain Service Provider [Member]

Disclosure of classes of share capital [line items]

7,500

$ 2.14

Certain Executive Officers [Member]

Disclosure of classes of share capital [line items]

250,000

$ 2.14

Disclosure of classes of share capital [line items]

$ 316,000

Former CEO [Member]

31,502

$ 1.98

General and administrative expenses reversal | $

$ 37,000

$ 4,000

Investor Relations Services Agreement [Member]

Disclosure of classes of share capital [line items]

Service monthly fees | $

$ 5,000

Amendment To Business Development Services Agreement [Member]

Disclosure of classes of share capital [line items]

Service monthly fees | $

$ 5,000

Placement Agency agreement with GP Numenkari Inc [Member]

Disclosure of classes of share capital [line items]

Percentage of cash fees of total proceeds

10.00%

Percentage of number of shares issued to subscribers

10.00%

Placement Agency agreement with GP Numenkari Inc [Member] | Broker Warrants type 1 [Member]

Disclosure of classes of share capital [line items]

Percentage of number of shares issued to subscribers

10.00%

Placement Agency agreement with GP Numenkari Inc [Member] | Broker Warrants type 2 [Member]

$ 2.37

Disclosure of classes of share capital [line items]

Percentage of number of shares issued to subscribers

5.00%

Subscription agreements with select group of accredited investors for private placement [Member]

$ 2.96

Disclosure of classes of share capital [line items]

Proceeds from private placement | $

5,710,153

$ 13,500,000

Share issue price per share | $ / shares

$ 2.37

2,855,095

2,855,095

$ 2.96

Disclosure of classes of share capital [line items]

Exercisable over a three-years period from the date of issuance.

Consultant [Member]

Number of options exrercised to ordinary shares

31,954

31,954

Value of options exercised | $

$ 68,000

Consultant [Member] | Share-based Compensation Expense [member] | Restricted Share Units [Member]

Disclosure of classes of share capital [line items]

Transaction costs | $

$ 52,766

Consultant [Member] | Investor Relations Services Agreement [Member]

Disclosure of classes of share capital [line items]

Number of shares vested

7,000

Consultant [Member] | Investor Relations Services Agreement [Member] | Restricted Share Units [Member]

Disclosure of classes of share capital [line items]

28,000

Consultant [Member] | Investor Relations Services Agreement [Member] | Restricted Share Units [Member] | Vest In Three Equal Installments [Member]

$ 53,200

Number of shares vested

21,000

Disclosure of classes of share capital [line items]

Number of shares vested

21,000

Consultant [Member] | Amendment To Business Development Services Agreement [Member]

Disclosure of classes of share capital [line items]

79,760

$ 1.06

The options vests over 6 months in six equal installments from October 1, 2020.

Executive officers and former Executive officer [Member]

$ 35,094

Disclosure of classes of share capital [line items]

Number of options exrercised to ordinary shares

662,251

662,251

Value of options exercised | $

$ 138,000

[1]	The total intrinsic value of options exercised during the year ended December 31, 2020 was approximately $22,048.

SHARE CAPITAL (Schedule of Composed of Ordinary Shares) (Details) - ₪ / shares	Dec. 31, 2020	Dec. 31, 2019	Mar. 17, 2013
Disclosure of classes of share capital [abstract]
Authorized	140,010,000	140,010,000
Issued	21,057,922	17,864,684
Par value per share	₪ 0.0000769	₪ 0.0000769	₪ 0.0000769

SHARE CAPITAL (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2020 Years $ / shares	Dec. 31, 2019 Years $ / shares	Dec. 31, 2018 Years $ / shares
Statement Line Items [Line Items]
Exercise price \| $ / shares		$ 3.12	$ 6.31
Dividend yield
Expected volatility		71.00%	68.00%
Risk-free interest rate		1.86%	2.23%
Expected life - in years \| Years		9.37	4.07
Bottom of range [Member]
Statement Line Items [Line Items]
Exercise price \| $ / shares	$ 1.06
Expected volatility	66.35%
Risk-free interest rate	0.16%
Expected life - in years \| Years	2.75
Top of range [Member]
Statement Line Items [Line Items]
Exercise price \| $ / shares	$ 2.14
Expected volatility	71.00%
Risk-free interest rate	0.58%
Expected life - in years \| Years	6.1

SHARE CAPITAL (Schedule of Changes in Number of Options and Weighted Average Exercise Prices) (Details)

12 Months Ended

Dec. 31, 2020

USD ($)

$ / shares

Dec. 31, 2019

$ / shares

Dec. 31, 2018

$ / shares

Number of options

Outstanding at beginning of year | shares

2,847,600

2,438,410

3,044,990

Expired | shares

(226,106)

(91,000)

Forfeited | shares

(589,793)

(14,690)

(718,120)

Exercised | shares

^[1]

(31,954)

(662,251)

(31,460)

Granted | shares

570,362

1,177,131

143,000

Outstanding at end of year | shares

2,570,109

2,847,600

2,438,410

Exercisable at end of year | shares

1,791,687

1,525,618

1,837,160

Weighted average exercise price

Outstanding at beginning of year | $ / shares

$ 4.74

$ 4.36

$ 4.59

Expired | $ / shares

2.68

6.31

Forfeited | $ / shares

2.7

4.44

5.73

Exercised | $ / shares

^[1]

2.11

0.21

Granted | $ / shares

1.98

3.12

5.35

Outstanding at end of year | $ / shares

4.85

4.74

4.36

Exercisable at end of year | $ / shares

$ 5.49

$ 5.62

$ 1.67

Intrinsic value | $

$ 22,048

[1]	The total intrinsic value of options exercised during the year ended December 31, 2020 was approximately $22,048.

SHARE CAPITAL (Schedule of Information about Exercise Price and Remaining Contractual Life of Outstanding Options) (Details)

12 Months Ended

Dec. 31, 2020

$ / shares

Dec. 31, 2019

$ / shares

Dec. 31, 2018

Dec. 31, 2017

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Exercise Price One [Member]

2,570,109

2,847,600

2,438,410

3,044,990

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

4,680

^[1]

Exercise Price Two [Member]

1 year 9 months 11 days

2 years 9 months 14 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

79,760

$ 1.06

Exercise Price Three [Member]

4 years 10 months 6 days

0 years

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

11,050

$ 1.85

Exercise Price Four [Member]

0 years

1 year 2 months 19 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

65,000

$ 2.11

Exercise Price Five [Member]

0 years

18 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

431,800

$ 2.14

Exercise Price Six [Member]

9 years 3 months 4 days

0 years

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

64,023

$ 2.53

Exercise Price Seven [Member]

8 years 10 months 21 days

9 years 10 months 21 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

696,587

$ 2.75

Exercise Price Eight [Member]

0 years

9 years 7 months 6 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

65,693

$ 3.10

Exercise Price Nine [Member]

3 years 10 months 21 days

4 years 10 months 21 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

198,120

203,970

$ 3.69

Exercise Price Ten [Member]

1 year 4 months 9 days

2 years 4 months 9 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

332,953

340,828

$ 3.97

Exercise Price Eleven [Member]

7 years 10 months 28 days

9 years 18 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

1,245,790

1,248,479

$ 6.31

Exercise Price Twelve [Member]

5 years 26 days

5 years 10 months 6 days

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

147,290

$ 7.54